Most importantly, alpelisib therapy in NSGS mice bearing nilotinib-resistant K562 cells significantly reduces leukemia burden and increases the survival time of leukemic mice, mechanistically through suppression of PI3K signaling mediators like F2R, Cyclin D1, and PDGFR. This evidence concerns the gene F2R and leukemia.